Ampersand Biomedicines Secures $65M Series B to Accelerate Next-Gen AND-Body™ Therapeutics

Ampersand Biomedicines, a pioneering force in the realm of precision medicine, is excited to announce that it has successfully raised $65,000,000 in its latest funding round. Founded in 2020 at Flagship Labs, a unit of Flagship Pioneering, the company has rapidly positioned itself at the forefront of designing programmable medicines that work precisely where needed in the body and nowhere else. At the heart of this breakthrough is Ampersand’s state-of-the-art computationally powered Address, Navigate, Design (AND)™ Platform, an innovative system that continually learns the rules for identifying optimal localizer targets. Leveraging advanced algorithms and vast biological data, the platform refines its ability to design across the complex space of localizers and actuators to engineer increasingly sophisticated AND-Body™ therapeutics. These therapeutics are meticulously crafted to navigate the delicate balance between molecular physical constraints and the intricate biological characteristics of disease targets, ensuring that treatments effectively focus on the site of disease while sparing healthy tissue or cells from unintended effects. The fresh infusion of capital will be strategically directed towards accelerating research and development, enhancing the AND™ Platform capabilities, and expediting clinical studies that are poised to transform the therapeutic landscape. With this commitment to innovation and precision, Ampersand Biomedicines is set to redefine the future of medicine by offering tailored treatments designed to work solely at the afflicted sites in the body. This funding milestone not only fortifies Ampersand’s market position but also signals a promising new chapter in the evolution of programmable medicine dedicated to improving patient outcomes while minimizing systemic risks.